AMGEN® Revision Number: 6

IMDELLTRA™ Safety Data Sheet

Revision Number: 6 Date Issued 05-Mar-2025

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERSTANDING

1.1 Product identifier

Product Name: IMDELLTRATM
Common Name: Tarlatamab-dlle

Chemical Name: Anti-DLL3 half-life extended bispecific T-cell engager molecule

Synonyms: IMDYLLTRA ™, AMG 757

1.2 Relevant identified uses of the substance or mixture and uses advised against

Recommended Use: Pharmaceutical

Uses advised against: No information available

Manufacturer: Emergency Telephone Number:

Amgen Inc. Chemtrec

One Amgen Center Drive NORTH AMERICA 1-800-424-9300, Thousand Oaks, California 91320-1799 INTERNATIONAL 1-703-527-3887

1-805-447-7233 1-805-447-1000

2. HAZARDS IDENTIFICATION

Emergency Overview

Pharmaceutical product intended for clinical and commercial manufacturing purposes only. Product contains tarlatamab-dlle, active ingredient for the treatment of small cell lung cancer (SCLC) and relapsed/refractory neuroendocrine prostate cancer (NEPC). The toxicity and potency of this chemical are not fully known. Avoid inhalation, skin contact, eye contact and accidental ingestion. Does not meet GHS classification criteria and therefore is not classified.

2.1 - Classification of the drug substance or mixture (drug product in final form, not applicable)
REGULATION (EC) No 1272/2008, WHMIS 2015 (Health Canada), and Hazard Communication Standard No. 1910.1200 (US OSHA)

Not classified

2.2 Label elements

Not classified

2.3 Other Hazards No information available

AMGEN®

IMDELLTRA™ Safety Data Sheet

Revision Number: 6 Date Issued 05-Mar-2025

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Ingredients: See below

Chemical Name: Anti-DLL3 half-life extended bispecific T-cell engager molecule

CAS-No: 2307488-83-9

Tarlatamab-dlle is supplied as a sterile, single use, preservative free lyophilized drug product with a deliverable dose of 1 or 10 mg/vial. The drug product is formulated with L-glutamic acid, sucrose, and polysorbate 80, pH 4.2. Tarlatamab-dlle is intended for reconstitution with sterile water for injection and dilution in an IV bag with IV Solution Stabilizer (IVSS) and saline.

4. FIRST AID MEASURES

4.1 Description of first-aid measures

Eye Contact: In the case of contact with eyes, rinse immediately with plenty of water and seek medical

advice.

Skin Contact: Wash off immediately with soap and plenty of water removing all contaminated clothes and

shoes. Consult a physician if necessary.

Inhalation: Move to fresh air. If symptoms persist, call a physician.

Ingestion: If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never

give anything by mouth to an unconscious person.

Notes to Physician: Treat symptomatically.

5. FIRE-FIGHTING MEASURES

5.1 Extinguishing media

Flammable Properties: No information available.

Extinguishing Media: Use extinguishing measures that are appropriate to local circumstances and the

surrounding environment.

5.2 Special hazards arising from the substance or mixture

Hazardous Combustion Products: No information available.

5.3 Advice for firefighters

Protective Equipment and As in any fire, wear self-contained breathing apparatus pressure-demand, NIOSH

Precautions for Firefighters: (approved) and full protective gear.



Date Issued 05-Mar-2025

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Spill Procedures:

If material is released or spilled, cordon off spill area. Take proper precautions to minimize exposure by using appropriate personal protective equipment in cleaning up a spill. If in powder form, wet down spilled material to minimize airborne dispersion. Soak up material with absorbent e.g., paper towels, and wash spill area thoroughly with appropriate cleaning materials. Dispose of collected material in accordance with applicable waste disposal regulations. Avoid release to the environment.

7. HANDLING AND STORAGE

7.1 Precautions for Safe Handling

Handling and Storage:

Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke in work areas. Use adequate ventilation to minimize exposure. Wash hands, face and other potentially exposed areas immediately after handling this material. Remove contaminated clothing prior to entering eating areas. Clean protective equipment thoroughly after each use. Store

in a well ventilated area.



Revision Number: 6 Date Issued 05-Mar-2025

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters

Occupational Exposure Limit: No exposure guidelines established by ACGIH, NIOSH or OSHA. Amgen recommends an

occupational exposure limit (OEL) of 5 µg/m³ as an 8-hour time weighted average over a 40-hour work week. The OEL is designed as an acceptable airborne concentration of a substance for which it is believed that workers may be repeatedly exposed day after day without adverse health effects. Tarlatamab-dlle has been classified per Amgen's Hazard Classification System as an Occupational Exposure Band 4 compound (5 µg/m³ - 20

 $\mu g/m^3$).

Engineering Controls: When practicable, handle material in enclosed processes or in processes with effective

local exhaust ventilation or within a chemical hood.

8.2 Exposure controls

Personal Protective Equipment

Eye/face Protection: Wear safety glasses with side shields, chemical splash goggles, or safety glasses with side

shields and a full-face shield to prevent contact with eyes. The choice of protection should

be based on the job activity and potential for exposure to the eyes and face.

Skin Protection: Use gloves or other appropriate personal protective equipment if skin contact with

formulation is possible. Wear lab coat or other protective over garment if splashing is possible. The choice of protection should be based on the job activity and potential for skin

contact.

Respiratory Protection: When possible, handle material in enclosed processes or containers. If it is properly

handled with effective local exhaust ventilation or containment, respiratory protection may not be needed. For procedures involving larger quantities or dust/aerosol generating procedures such as weighing or a large transfer of liquids, an air-purifying respirator with NIOSH approval for dusts and mists may be needed. The choice of protection should be

based on the job activity and the potential for exposure.

Other: Wash hands, face and other potentially exposed areas after handling material (especially

before eating, drinking or smoking). Clean protective equipment thoroughly after each use.

8.3 Environmental exposure controls

Environmental Exposure Controls Avoid release to the environment.



Revision Number: 6 Date Issued 05-Mar-2025

9. PHYSICAL AND CHEMICAL PROPERTIES

White to off-white Appearance: Physical State: Lyophilized powder

Molecular Weight: 105 kDa

No information available Odor: **Odor Threshold:** No information available 4.2 (formulated drug product) pH: **Melting Point:** No information available **Boiling point** No information available Flash Point: No information available **Evaporation Rate:** No information available Lower explosive limit: No information available **Upper explosive limit:** No information available Vapor Pressure: No information available Vapor Density (air = 1): No information available Relative density: No information available

Water Solubility: No information available **Partition Coefficient (log Kow):** No information available No information available Viscosity:

10. STABILITY AND REACTIVITY

No information available 10.1 Reactivity

No information available 10.2 Chemical stability

10.3 Possibility of hazardous No information available

reactions

10.4 Conditions to avoid No Information available

10.5 Incompatible materials No information available

10.6 Hazardous

decomposition products

No information available

10.7 Other information None



Revision Number: 6 Date Issued 05-Mar-2025

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute Toxicity: No information available

Skin corrosion/irritation: Does not meet GHS Classification Criteria and therefore is not classified. Does not meet GHS Classification Criteria and therefore is not classified. Serious eye damage/eye irritation: Does not meet GHS Classification Criteria and therefore is not classified. Respiratory or skin sensitization: Does not meet GHS Classification Criteria and therefore is not classified. Germ cell mutagenicity: Carcinogenicity: Does not meet GHS Classification Criteria and therefore is not classified. Reproductive toxicity: Does not meet GHS Classification Criteria and therefore is not classified. STOT - single exposure: Does not meet GHS Classification Criteria and therefore is not classified. Does not meet GHS Classification Criteria and therefore is not classified. STOT - repeated exposure:

Aspiration Hazard: No information available

12. ECOLOGICAL INFORMATION

12.1 Toxicity

Ecotoxicity effects: No information available

12.2 Persistence and degradability

Persistence/Degradability: No information available

12.3 Bioaccumulative potential

Bioaccumulation/ Accumulation: No information available

12.4 Mobility in soil

Mobility in Environmental Media: No information available

12.5 Results of PBT and vPvB assessment

Results of PBT and vPvB assessment: No information available

12.6 Other adverse effects

Other Adverse Effects: No information available

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste Disposal Method: Dispose of waste according to prescribed federal, state, local and competent authority

guidelines.

AMGEN®

IMDELLTRA™ Safety Data Sheet

Revision Number: 6 Date Issued 05-Mar-2025

14. TRANSPORT INFORMATION

DOT: Not regulated by U.S. DOT, IATA, IMDG or ADR.

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

International Inventories

TSCA:

EINECS/ELINCS

DSL/NDSL

PICCS:

ENCS:

CHINA:

AICS:

KECL:

Legend

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

EINECS/ELINCS - European Inventory of Existing Commercial Chemical Substances/EU List of Notified Chemical Substances

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

PICCS - Philippines Inventory of Chemicals and Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

AICS - Australian Inventory of Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

State Regulations

California Proposition 65: This product does not contain any Proposition 65 chemicals.

15.2 Chemical safety assessment

No CSA has been conducted.

AMGEN® Revision Number: 6

IMDELLTRA™ Safety Data Sheet

Date Issued 05-Mar-2025

16. OTHER INFORMATION

Revision Number: 6

To the best of our knowledge, the information provided here is accurate as of the date of the Safety Data Sheet (SDS). The information is specific to the material that is the subject of this SDS and may not be valid when this material is used in combination with any other materials or in any process. Each user should review the information provided here in the context of the user's intended manner of handling, using, processing, storing, transporting, and disposing of the material.

This information is provided without warranty or guarantee of any kind, whether express, implied or statutory, including without limitation warranty of fitness or merchantability for a particular purpose or noninfringement. No representation, warranty, or guarantee is made, and no liability is assumed, with respect to the material or the information contained in this SDS including without limitation its accuracy or completeness or the hazards of, or results obtained from, use of the material or the information contained here. Caution should be used in the handling, using, processing, storing, transporting, and disposing of the material.